"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...

Amidst a backdrop of economic uncertainty and inflation concerns, global markets have experienced a downturn, with U.S. stock indexes falling due to trade policy uncertainties and growth worries. In ...

Amidst a backdrop of economic uncertainty and inflation concerns, global markets have been grappling with trade policy shifts and fluctuating consumer sentiment. As investors navigate these turbulent ...

AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase using Hybrozyme platform technology.

S. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing deals in Q1 ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

KOSPI rises on Samsung Electronics while KOSDAQ falls with Alteogen decline KOSPI closes higher thanks to strong Samsung ...